Mangalam Drugs And Organics Limited has informed the Exchange about Amalgamation/Merger
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The National Company Law Tribunal (NCLT), Mumbai Bench, has directed Mangalam Drugs and Organics Limited (MDOL) to convene meetings of its equity shareholders and unsecured creditors on August 12, 2025, to consider a proposed merger by absorption. Under the scheme, two group companies — Mangalam Laboratories Private Limited (MLPL, a wholly owned subsidiary of MDOL) and Shri JB Pharma Private Limited (SJPPL) — will merge into MDOL. Since MLPL is wholly owned, no consideration will be paid. For SJPPL shareholders, the share exchange ratio is 265 equity shares of MDOL (face value Rs. 10 each) for every 1 equity share of SJPPL (face value Rs. 10 each). BSE and NSE had already issued their no-objection letters in January 2025. The appointed date for the merger is April 1, 2024. Both meetings will be held via video conferencing, with remote e-voting facilities available to shareholders and creditors.
This is a step forward in the group restructuring process and consolidation of pharmaceutical businesses under the listed entity. Existing MDOL shareholders will need to vote on the scheme, but since the merger primarily involves a wholly owned subsidiary and a private group company, it is unlikely to materially dilute equity. Approval at the shareholder and creditor meetings will be needed for the scheme to move to the next stage of NCLT sanction.